- Home
- ARW vs NUVL Comparison
ARW vs NUVL Comparison
Compare ARW & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARW
- NUVL
- Stock Information
- Founded
- ARW 1935
- NUVL 2017
- Country
- ARW United States
- NUVL United States
- Employees
- ARW N/A
- NUVL N/A
- Industry
- ARW Electronic Components
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- ARW Technology
- NUVL Health Care
- Exchange
- ARW Nasdaq
- NUVL Nasdaq
- Market Cap
- ARW 5.3B
- NUVL 5.6B
- IPO Year
- ARW N/A
- NUVL 2021
- Fundamental
- Price
- ARW $117.96
- NUVL $69.85
- Analyst Decision
- ARW Hold
- NUVL Strong Buy
- Analyst Count
- ARW 4
- NUVL 8
- Target Price
- ARW $121.25
- NUVL $115.50
- AVG Volume (30 Days)
- ARW 705.3K
- NUVL 625.4K
- Earning Date
- ARW 05-01-2025
- NUVL 05-08-2025
- Dividend Yield
- ARW N/A
- NUVL N/A
- EPS Growth
- ARW N/A
- NUVL N/A
- EPS
- ARW 7.28
- NUVL N/A
- Revenue
- ARW $27,813,081,000.00
- NUVL N/A
- Revenue This Year
- ARW $0.02
- NUVL N/A
- Revenue Next Year
- ARW $8.06
- NUVL N/A
- P/E Ratio
- ARW $16.28
- NUVL N/A
- Revenue Growth
- ARW N/A
- NUVL N/A
- 52 Week Low
- ARW $86.50
- NUVL $55.54
- 52 Week High
- ARW $137.80
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- ARW 68.29
- NUVL 46.22
- Support Level
- ARW $114.45
- NUVL $63.56
- Resistance Level
- ARW $119.46
- NUVL $78.97
- Average True Range (ATR)
- ARW 2.92
- NUVL 3.46
- MACD
- ARW 0.98
- NUVL -0.38
- Stochastic Oscillator
- ARW 91.32
- NUVL 40.84
About ARW Arrow Electronics Inc.
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.